Four Award Winning Top Pharmaceuticals Stocks Financial News (ARIA, CYTX, VNDA, SNY)

Los Angelas, CA -- (SBWIRE) -- 12/17/2012 -- Ariad Pharmaceuticals (NASDAQ:ARIA) which fell as much as 20%, after announcing that the Food and Drug Administration has approved Iclusig (formerly ponatinib) for the treatment of a rare blood borne and bone marrow cancer ... with a catch. The once-daily drug can now be used to treat chronic myeloid leukemia, or CML, and Philadelphia chromosome positive acute lymphoblastic leukemia. Both diseases are rare, which granted Iclusig orphan drug and accelerated review status. However, the FDA is also requiring a warning on the box for physicians and patients that Iclusig can cause blood clots and liver toxicity. But its bone-tumor drug ridaforolimus was rejected in Europe. All isn't lost for that formula, though, as it might still prove effective against other cancers. The company's recent quarterly results were mixed, and it has been spending heavily on research and development.

Need Guidance On Buy and Sell Recommendation: Click Here

Cytori Therapeutics (NASDAQ:CYTX) reported Friday the sale of 7.02 million shares of its common stock in an underwritten public offering at a price to the public of $2.85. The net offering proceeds to the firm are anticipated to be about $18.5 million after the subtraction of underwriting discounts and commissions along with other estimated offering expenses but excluding any exercise of the underwriters over-allotment option. Cytori Therapeuti (NGM:CYTX) reported EPS of -0.613. For the Current Fiscal year, the company is expected to report EPS of -0.63. For the Next Quarter and Next Year, the company is expected to report EPS of -0.14 and -0.47 respectively. At Current Market Price, CYTX is in distance of -21.87% from its 50-day Moving Average price of $3.6349 and -13.10% from its 200-day Moving Average price of $3.2681.

How Should Investors React to CYTX Now? Find Out Here

Vanda Pharmaceuticals (NASDAQ:VNDA) reported on Friday that the European Medicines Agency’s Committee for Medicinal Product for Human Use has released a negative opinion, recommending against approval of Fanaptum (oral iloperidone tablets) for the treatment of schizophrenia in adult patients in the European Union. The Committee’s opinion was that the benefits of Fanaptum did not surpass its risks and thus recommended against marketing authorization at this time. For its part, Vanda will appeal this opinion and ask for a re-examination of the decision.

Are These Stock Buy or Sell? Get a Current Trend Analysis Report From Here

The Sanofi-Aventis (NYSE:SNY) subsidiary Genzyme and Isis Pharmaceuticals (NASDAQ:ISIS) said that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a negative opinion for their marketing authorization application for Kynamro (mipomersen) for the treatment of patients suffering from Homozygous Familial Hypercholesterolaemia. However, Genzyme will request a re-examination of the Committee opinion. Sanofi American D (NYSE:SNY) reported EPS of 2.925. For the Current Fiscal year, the company is expected to report EPS of 6.95. For the Next Quarter and Next Year, the company is expected to report EPS of 1.86 and 6.94 respectively. At Current Market Price, SNY is in distance of +5.44% from its 50-day Moving Average price of $44.5939 and +14.27% from its 200-day Moving Average price of $41.1484.

Is SNY A Secure Investment? Watch Out An Over View of SNY Here

Disclaimer
Neither HotPennyStockNews.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by HotPennyStockNews.com, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation. HotPennyStockNews.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through HotPennyStockNews.com. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to loose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein..

Contact:
hotpennystocknews.com
info@hotpennystocknews.com